Cell line name |
A2780/TPT |
Accession |
CVCL_4V45 |
Resource Identification Initiative |
To cite this cell line use: A2780/TPT (RRID:CVCL_4V45) |
Comments |
Population: African American. Selected for resistance to: ChEBI; CHEBI_63632; Topotecan. Derived from site: In situ; Ovary; UBERON=UBERON_0000992. |
Sequence variations |
- Mutation; HGNC; HGNC:795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu365Lys (c.1093G>A); ClinVar=VCV000419222; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:17271; RRAS2; Simple; p.Gln72Leu (c.215A>T); ClinVar=VCV000009447; Zygosity=Homozygous (from parent cell line).
|
Disease |
Ovarian endometrioid adenocarcinoma (NCIt: C7979) Endometrioid carcinoma of ovary (ORDO: Orphanet_454723) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0134 (A2780) |
Sex of cell |
Female |
Age at sampling |
Age unspecified |
Category |
Cancer cell line |
Publications | PubMed=14693055 Jia P., Wu S.-B., Xu Q., Wu M.-F., Gao Q.-L., Liao G.-N., Lu Y.-P., Ma D. Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells. Ai Zheng 22:1296-1300(2003) DOI=10.3969/j.issn.1004-7379.2004.03.003 Jia P., Li F., Wu M.-F., Liao G.-N., Lu Y.-P., Ma D. Establishment of topotecan-resistant ovarian cancer cell line. Xian Dai Fu Chan Ke Jin Zhan 13:174-177(2004) PubMed=15196431; DOI=10.3760/j.issn:0253-3766.2004.03.003 Jia P., Wu S.-B., Li F., Xu Q., Wu M.-F., Liao G.-N., Lu Y.-P., Ma D. The mechanism of topotecan resistance in ovarian cancer cell line. Zhonghua Zhong Liu Za Zhi 26:139-142(2004) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_4V45
|
Encyclopedic resources |
Wikidata; Q54606611
|
Entry history |
Entry creation | 14-Dec-2015 |
Last entry update | 10-Apr-2025 |
Version number | 12 |
---|